PDF(Pubmed)
Abstract：
Legumain (LGMN) has been demonstrated to be overexpressed not just in breast, prostatic, and liver tumor cells, but also in the macrophages that compose the tumor microenvironment. This supports the idea that LGMN is a pivotal protein in regulating tumor development, invasion, and dissemination. Targeting LGMN with siRNA or chemotherapeutic medicines and peptides can suppress cancer cell proliferation in culture and reduce tumor growth in vivo. Furthermore, legumain can be used as a marker for cancer detection and targeting due to its expression being significantly lower in normal cells compared to tumors or tumor-associated macrophages (TAMs). Tumor formation is influenced by aberrant expression of proteins and alterations in cellular architecture, but the tumor microenvironment is a crucial deciding factor. Legumain (LGMN) is an in vivo-active cysteine protease that catalyzes the degradation of numerous proteins. Its precise biological mechanism encompasses a number of routes, including effects on tumor-associated macrophage and neovascular endothelium in the tumor microenvironment. The purpose of this work is to establish a rationale for thoroughly investigating the function of LGMN in the tumor microenvironment and discovering novel tumor early diagnosis markers and therapeutic targets by reviewing the function of LGMN in tumor genesis and progression and its relationship with tumor milieu.
摘要：
Legumain（LGMN）已被证明不仅在乳房中过度表达，前列腺,和肝脏肿瘤细胞，而且在构成肿瘤微环境的巨噬细胞中。这支持LGMN是调节肿瘤发展的关键蛋白的观点。入侵,和传播。用siRNA或化疗药物和肽靶向LGMN可以抑制培养物中的癌细胞增殖并减少体内肿瘤生长。此外，由于与肿瘤或肿瘤相关巨噬细胞（TAMs）相比，其在正常细胞中的表达显着降低，因此可以用作癌症检测和靶向的标志物。肿瘤形成受蛋白质异常表达和细胞结构改变的影响。但肿瘤微环境是一个至关重要的决定因素。Legumain（LGMN）是一种体内活性半胱氨酸蛋白酶，可催化许多蛋白质的降解。其精确的生物学机制包括许多途径，包括对肿瘤微环境中肿瘤相关巨噬细胞和新生血管内皮的影响。这项工作的目的是通过回顾LGMN在肿瘤发生和发展中的功能及其与肿瘤环境的关系，为深入研究LGMN在肿瘤微环境中的功能并发现新的肿瘤早期诊断标志物和治疗靶标奠定基础。
